AU2012266541A1 - Combination comprising umeclidinium and a corticosteroid - Google Patents

Combination comprising umeclidinium and a corticosteroid Download PDF

Info

Publication number: AU2012266541A1
Authority: AU; Australia
Prior art keywords: product according; compound; formula; dose; corticosteroid
Prior art date: 2011-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2012266541A

Other languages

English (en)

Inventor

Glenn Crater

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-08

Filing date

2012-06-01

Publication date

2014-01-09

2012-06-01 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2014-01-09 Publication of AU2012266541A1 publication Critical patent/AU2012266541A1/en

Status Abandoned legal-status Critical Current

Links

239000003246 corticosteroid Substances 0.000 title claims abstract description 58
FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 title description 3
229960004258 umeclidinium Drugs 0.000 title description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
201000010099 disease Diseases 0.000 claims abstract description 10
239000000203 mixture Substances 0.000 claims description 89
150000001875 compounds Chemical class 0.000 claims description 75
PEJHHXHHNGORMP-AVADPIKZSA-M umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-AVADPIKZSA-M 0.000 claims description 57
229960004541 umeclidinium bromide Drugs 0.000 claims description 57
239000000047 product Substances 0.000 claims description 54
XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 52
229960001469 fluticasone furoate Drugs 0.000 claims description 52
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
150000001768 cations Chemical class 0.000 claims description 29
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 26
239000000843 powder Substances 0.000 claims description 26
239000013066 combination product Substances 0.000 claims description 24
229940127555 combination product Drugs 0.000 claims description 24
208000006673 asthma Diseases 0.000 claims description 23
239000008101 lactose Substances 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 23
229940112141 dry powder inhaler Drugs 0.000 claims description 21
235000019359 magnesium stearate Nutrition 0.000 claims description 18
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
239000003380 propellant Substances 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
230000002757 inflammatory effect Effects 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
208000027866 inflammatory disease Diseases 0.000 claims description 7
208000018569 Respiratory Tract disease Diseases 0.000 claims description 6
229960000289 fluticasone propionate Drugs 0.000 claims description 6
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 6
239000000443 aerosol Substances 0.000 claims description 5
150000001450 anions Chemical class 0.000 claims description 5
239000007921 spray Substances 0.000 claims description 5
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 4
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 claims description 4
239000006184 cosolvent Substances 0.000 claims description 4
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
229940071648 metered dose inhaler Drugs 0.000 claims description 3
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
229910002651 NO3 Inorganic materials 0.000 claims description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical group [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
229960003728 ciclesonide Drugs 0.000 claims description 2
229960002714 fluticasone Drugs 0.000 claims description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
150000005828 hydrofluoroalkanes Chemical group 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical group [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 2
229960002744 mometasone furoate Drugs 0.000 claims description 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Chemical group 0.000 claims description 2
210000002345 respiratory system Anatomy 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical group [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical group OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 claims 1
150000001805 chlorine compounds Chemical group 0.000 claims 1
239000003149 muscarinic antagonist Substances 0.000 abstract description 5
229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract description 4
230000001404 mediated effect Effects 0.000 abstract description 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 21
229960001375 lactose Drugs 0.000 description 20
229960001021 lactose monohydrate Drugs 0.000 description 12
239000002245 particle Substances 0.000 description 11
239000004480 active ingredient Substances 0.000 description 8
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
HCMAEEZVLLOLQF-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-2-yl]methanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CC(CC2)CC[N+]12CCOCC1=CC=CC=C1 HCMAEEZVLLOLQF-UHFFFAOYSA-N 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
-1 furanylcarbonyl Chemical group 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000006872 improvement Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000011418 maintenance treatment Methods 0.000 description 3
238000007726 management method Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
IVFHIIPWLILHCX-KVXXQBCDSA-N 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;[(6s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclo Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)CC3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 IVFHIIPWLILHCX-KVXXQBCDSA-N 0.000 description 2
229940123031 Beta adrenoreceptor agonist Drugs 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
208000000059 Dyspnea Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
230000001022 anti-muscarinic effect Effects 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
230000007883 bronchodilation Effects 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
229940127034 fluticasone furoate/vilanterol Drugs 0.000 description 2
239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000001294 propane Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
DYEHDACATJUKSZ-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane;bromide Chemical compound [Br-].C1CC2CC[NH+]1CC2 DYEHDACATJUKSZ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
102000017925 CHRM3 Human genes 0.000 description 1
101150060249 CHRM3 gene Proteins 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
239000013566 allergen Substances 0.000 description 1
150000001398 aluminium Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000001649 bromium compounds Chemical group 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
150000004777 chromones Chemical class 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000000428 dust Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000013125 spirometry Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
229940110309 tiotropium Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

AU2012266541A 2011-06-08 2012-06-01 Combination comprising umeclidinium and a corticosteroid Abandoned AU2012266541A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161494600P	2011-06-08	2011-06-08
US61/494,600		2011-06-08
PCT/EP2012/060444 WO2012168161A1 (fr)	2011-06-08	2012-06-01	Combinaison comprenant de l'uméclidinium et un corticoïde

Publications (1)

Publication Number	Publication Date
AU2012266541A1 true AU2012266541A1 (en)	2014-01-09

Family

ID=46201674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2012266541A Abandoned AU2012266541A1 (en)	2011-06-08	2012-06-01	Combination comprising umeclidinium and a corticosteroid

Country Status (20)

Country	Link
US (1)	US20140113888A1 (fr)
EP (1)	EP2717868A1 (fr)
JP (1)	JP2014516062A (fr)
KR (1)	KR20140041699A (fr)
CN (1)	CN103582477A (fr)
AU (1)	AU2012266541A1 (fr)
BR (1)	BR112013031572A2 (fr)
CA (1)	CA2838030A1 (fr)
CL (1)	CL2013003497A1 (fr)
CO (1)	CO6821951A2 (fr)
CR (1)	CR20130643A (fr)
DO (1)	DOP2013000290A (fr)
EA (1)	EA201391618A1 (fr)
IL (1)	IL229633A0 (fr)
MA (1)	MA35406B1 (fr)
MX (1)	MX2013014399A (fr)
PE (1)	PE20141048A1 (fr)
PH (1)	PH12013502497A1 (fr)
SG (1)	SG195262A1 (fr)
WO (1)	WO2012168161A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4578502A3 (fr)	2009-02-26	2025-10-08	Glaxo Group Limited	Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
WO2013100083A1 (fr)	2011-12-28	2013-07-04	旭化成イーマテリアルズ株式会社	Accumulateur redox ainsi que membrane électrolytique pour accumulateur redox
KR20140147891A (ko)	2012-04-13	2014-12-30	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	응집체 입자
GB201222679D0 (en)	2012-12-17	2013-01-30	Glaxo Group Ltd	Pharmaceutical combination products
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
JP6758196B2 (ja)	2014-05-28	2020-09-23	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Ｃｏｐｄの治療におけるフルチカゾンフランカルボン酸エステル
US20170119744A1 (en)	2014-06-18	2017-05-04	Cipla Limited	Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent
CN107200734B (zh) *	2016-03-18	2019-12-24	益方生物科技（上海）有限公司	奎宁环衍生物及其制备方法和用途
TR201712424A2 (tr) *	2017-08-21	2019-03-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2021236570A1 (fr) *	2020-05-18	2021-11-25	Anovent Pharmaceutical (U.S.), Llc	Formulation pharmaceutique contenant du remdésivir et ses métabolites actifs pour inhalation de poudre sèche
MX2023003847A (es) *	2020-10-02	2023-05-17	Colgate Palmolive Co	Composiciones y métodos prebióticos para el cuidado bucal.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
ES2122261T3 (es)	1993-03-17	1998-12-16	Minnesota Mining & Mfg	Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester.
US6126919A (en)	1997-02-07	2000-10-03	3M Innovative Properties Company	Biocompatible compounds for pharmaceutical drug delivery systems
CZ2003353A3 (cs)	2000-08-05	2003-05-14	Glaxo Group Limited	Estery steroidních thiokyselin
UA77656C2 (en) *	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB0201677D0 (en)	2002-01-25	2002-03-13	Glaxo Group Ltd	Medicament dispenser
SE527191C2 (sv) *	2003-06-19	2006-01-17	Microdrug Ag	Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
MY144753A (en) *	2004-04-27	2011-10-31	Glaxo Group Ltd	Muscarinic acetylcholine receptor antagonists
PE20060826A1 (es) *	2004-12-06	2006-10-08	Smithkline Beecham Corp	Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
GB0515584D0 (en)	2005-07-28	2005-09-07	Glaxo Group Ltd	Medicament dispenser
AR058289A1 (es)	2005-12-12	2008-01-30	Glaxo Group Ltd	Colector para ser usado en dispensador de medicamento
CN101801378A (zh) *	2007-09-12	2010-08-11	葛兰素集团有限公司	治疗药物的新型组合
EP4578502A3 (fr) *	2009-02-26	2025-10-08	Glaxo Group Limited	Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
GB0921075D0 (en) *	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents

2012
- 2012-06-01 KR KR1020147000491A patent/KR20140041699A/ko not_active Withdrawn
- 2012-06-01 WO PCT/EP2012/060444 patent/WO2012168161A1/fr not_active Ceased
- 2012-06-01 EA EA201391618A patent/EA201391618A1/ru unknown
- 2012-06-01 CA CA2838030A patent/CA2838030A1/fr not_active Abandoned
- 2012-06-01 JP JP2014514008A patent/JP2014516062A/ja active Pending
- 2012-06-01 CN CN201280027664.6A patent/CN103582477A/zh active Pending
- 2012-06-01 PE PE2013002753A patent/PE20141048A1/es not_active Application Discontinuation
- 2012-06-01 EP EP12725047.0A patent/EP2717868A1/fr not_active Withdrawn
- 2012-06-01 AU AU2012266541A patent/AU2012266541A1/en not_active Abandoned
- 2012-06-01 US US14/124,276 patent/US20140113888A1/en not_active Abandoned
- 2012-06-01 PH PH1/2013/502497A patent/PH12013502497A1/en unknown
- 2012-06-01 SG SG2013089123A patent/SG195262A1/en unknown
- 2012-06-01 BR BR112013031572A patent/BR112013031572A2/pt not_active IP Right Cessation
- 2012-06-01 MX MX2013014399A patent/MX2013014399A/es unknown
2013
- 2013-11-26 IL IL229633A patent/IL229633A0/en unknown
- 2013-12-05 CL CL2013003497A patent/CL2013003497A1/es unknown
- 2013-12-06 DO DO2013000290A patent/DOP2013000290A/es unknown
- 2013-12-09 CO CO13287946A patent/CO6821951A2/es not_active Application Discontinuation
- 2013-12-09 CR CR20130643A patent/CR20130643A/es unknown
2014
- 2014-01-03 MA MA36643A patent/MA35406B1/fr unknown

Also Published As

Publication number	Publication date
DOP2013000290A (es)	2014-03-16
MX2013014399A (es)	2014-03-21
PH12013502497A1 (en)	2019-07-17
CL2013003497A1 (es)	2014-07-04
CN103582477A (zh)	2014-02-12
EP2717868A1 (fr)	2014-04-16
NZ618166A (en)	2016-01-29
CR20130643A (es)	2014-02-04
KR20140041699A (ko)	2014-04-04
CO6821951A2 (es)	2013-12-31
EA201391618A1 (ru)	2014-05-30
PE20141048A1 (es)	2014-09-08
SG195262A1 (en)	2013-12-30
JP2014516062A (ja)	2014-07-07
WO2012168161A1 (fr)	2012-12-13
US20140113888A1 (en)	2014-04-24
CA2838030A1 (fr)	2012-12-13
MA35406B1 (fr)	2014-09-01
IL229633A0 (en)	2014-01-30
BR112013031572A2 (pt)	2017-03-21

Publication	Publication Date	Title
US12396986B2 (en)	2025-08-26	Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonist
AU2012266541A1 (en)	2014-01-09	Combination comprising umeclidinium and a corticosteroid
US9795561B2 (en)	2017-10-24	Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
CA2972939A1 (fr)	2016-07-21	Combinaison pharmaceutique
HK40112155A (en)	2025-01-17	Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
NZ618166B2 (en)	2016-05-03	Combination comprising umeclidinium and a corticosteroid

Legal Events

Date	Code	Title	Description
2016-08-11	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted